Roche inks $774M pact

Invitrogen Applera's Applied Biosystems $6.7B merger

Invitrogen has agreed to acquire all of the shares of Applera's Applied Biosystems in a $6.7 billion cash and stock deal. The companies are two of the biggest suppliers to the drug development business.

Roche ThromboGenics and BioInven$774M deal

In the deal, ThromboGenics gets a whopping $77.4 million upfront payment from Roche, with close to $700 million in milestones that will be split 60/40 between ThromboGenics and BioInvent.

Boehringer IngelheimActimis Pharmaceuticals$515M buyout

Boehringer is buying Actimis Pharmaceuticals, which is developing asthma and allergy drugs.

Kyowa HakkoAlnylam Pharmaceuticals $93M development pact

Cambridge, MA-based Alnylam will develop an Respiratory Syncytial Virus therapy for Asian markets.

Parexel ClinPhone$182M buyout

CRO Parexel has made a $182 million bid for U.K.-based ClinPhone, but it may be facing competition from Quintiles, the world's largest private CRO.

Stiefel Laboratories Barrier Therapeutics$148M buyout

Barrier Therapeutics is a developer of dermatology products.

Roche inks $774M pact

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.